IL17A and inflammatory bowel disease: Noteworthy, more recent studies implied relevant alterations in the structural composition of the gut “virome” in IBD [114], and two recent clinical trials showed that blocking IL-17A with secukinumab or IL-17RA with brodalumab worsened Crohn’s disease, with some patients developing mucocutaneous candidiasis ventilating a role for the gut mycobiome in IBD, which has been implicated in intestinal inflammation as well [115, 116].